San Diego CA— Curebound announced a $500,000 donation to UC San Diego (UCSD) and La Jolla Institute for Immunology (LJI), completing a pledge to a novel cancer immunotherapy trial initiated by UCSD, LJI and Immunotherapy Foundation. The active phase I tumor-infiltrating lymphocyte (TIL) trial studies a form of personalized cancer immunotherapy that has been in development for decades, but is only now able to accurately produce individualized treatments due to recent advancements in technology. Curebound’s donation will ensure the trial’s completion, which holds great promise for patients and progress in cancer immuno-oncology.
“On behalf of the Immunotherapy Foundation community, we’re delighted to present the final donation toward the TIL trial to our partners at UC San Diego,” said Fernanda Whitworth, Co-Founder of Curebound. “We are excited to embark on this next chapter to raise and invest $100 million into innovative cancer research here in San Diego, a vision that my husband Ralph would have been very proud of.”
Curebound will continue to initiate cutting-edge research collaborations between San Diego’s top cancer centers as the organization awards further grant funding throughout the year.